FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226156778> ?p ?o ?g. }

• W4226156778 endingPage "74" @default.
• W4226156778 startingPage "1" @default.
• W4226156778 abstract "Background Uterine fibroids are the most common tumour in women of reproductive age and are associated with heavy menstrual bleeding, abdominal discomfort, subfertility and reduced quality of life. For women wishing to retain their uterus and who do not respond to medical treatment, myomectomy and uterine artery embolisation are therapeutic options. Objectives We examined the clinical effectiveness and cost-effectiveness of uterine artery embolisation compared with myomectomy in the treatment of symptomatic fibroids. Design A multicentre, open, randomised trial with a parallel economic evaluation. Setting Twenty-nine UK hospitals. Participants Premenopausal women who had symptomatic uterine fibroids amenable to myomectomy or uterine artery embolisation were recruited. Women were excluded if they had significant adenomyosis, any malignancy or pelvic inflammatory disease or if they had already had a previous open myomectomy or uterine artery embolisation. Interventions Participants were randomised to myomectomy or embolisation in a 1 : 1 ratio using a minimisation algorithm. Myomectomy could be open abdominal, laparoscopic or hysteroscopic. Embolisation of the uterine arteries was performed under fluoroscopic guidance. Main outcome measures The primary outcome was the Uterine Fibroid Symptom Quality of Life questionnaire (with scores ranging from 0 to 100 and a higher score indicating better quality of life) at 2 years, adjusted for baseline score. The economic evaluation estimated quality-adjusted life-years (derived from EuroQol-5 Dimensions, three-level version, and costs from the NHS perspective). Results A total of 254 women were randomised – 127 to myomectomy (105 underwent myomectomy) and 127 to uterine artery embolisation (98 underwent embolisation). Information on the primary outcome at 2 years was available for 81% ( n = 206) of women. Primary outcome scores at 2 years were 84.6 (standard deviation 21.5) in the myomectomy group and 80.0 (standard deviation 22.0) in the uterine artery embolisation group (intention-to-treat complete-case analysis mean adjusted difference 8.0, 95% confidence interval 1.8 to 14.1, p = 0.01; mean adjusted difference using multiple imputation for missing responses 6.5, 95% confidence interval 1.1 to 11.9). The mean difference in the primary outcome at the 4-year follow-up time point was 5.0 (95% CI –1.4 to 11.5; p = 0.13) in favour of myomectomy. Perioperative and postoperative complications from all initial procedures occurred in similar percentages of women in both groups (29% in the myomectomy group vs. 24% in the UAE group). Twelve women in the uterine embolisation group and six women in the myomectomy group reported pregnancies over 4 years, resulting in seven and five live births, respectively (hazard ratio 0.48, 95% confidence interval 0.18 to 1.28). Over a 2-year time horizon, uterine artery embolisation was associated with higher costs than myomectomy (mean cost £7958, 95% confidence interval £6304 to £9612, vs. mean cost £7314, 95% confidence interval £5854 to £8773), but with fewer quality-adjusted life-years gained (0.74, 95% confidence interval 0.70 to 0.78, vs. 0.83, 95% confidence interval 0.79 to 0.87). The differences in costs (difference £645, 95% confidence interval –£1381 to £2580) and quality-adjusted life-years (difference –0.09, 95% confidence interval –0.11 to –0.04) were small. Similar results were observed over the 4-year time horizon. At a threshold of willingness to pay for a gain of 1 QALY of £20,000, the probability of myomectomy being cost-effective is 98% at 2 years and 96% at 4 years. Limitations There were a substantial number of women who were not recruited because of their preference for a particular treatment option. Conclusions Among women with symptomatic uterine fibroids, myomectomy resulted in greater improvement in quality of life than did uterine artery embolisation. The differences in costs and quality-adjusted life-years are very small. Future research should involve women who are desiring pregnancy. Trial registration This trial is registered as ISRCTN70772394. Funding This study was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme, and will be published in full in Health Technology Assessment ; Vol. 26, No. 22. See the NIHR Journals Library website for further project information." @default.
• W4226156778 created "2022-05-05" @default.
• W4226156778 creator A5003522548 @default.
• W4226156778 creator A5010249392 @default.
• W4226156778 creator A5028055912 @default.
• W4226156778 creator A5030389292 @default.
• W4226156778 creator A5042009950 @default.
• W4226156778 creator A5045595046 @default.
• W4226156778 creator A5066802292 @default.
• W4226156778 creator A5074353532 @default.
• W4226156778 creator A5076563921 @default.
• W4226156778 creator A5085303209 @default.
• W4226156778 creator A5087241179 @default.
• W4226156778 creator A5088277389 @default.
• W4226156778 date "2022-04-01" @default.
• W4226156778 modified "2023-10-18" @default.
• W4226156778 title "Uterine artery embolisation versus myomectomy for premenopausal women with uterine fibroids wishing to avoid hysterectomy: the FEMME RCT" @default.
• W4226156778 cites W134882596 @default.
• W4226156778 cites W1493322556 @default.
• W4226156778 cites W1495928164 @default.
• W4226156778 cites W1542775365 @default.
• W4226156778 cites W1853819257 @default.
• W4226156778 cites W1870591762 @default.
• W4226156778 cites W1949976355 @default.
• W4226156778 cites W1970226997 @default.
• W4226156778 cites W1979037641 @default.
• W4226156778 cites W1994222210 @default.
• W4226156778 cites W1996284739 @default.
• W4226156778 cites W2021171884 @default.
• W4226156778 cites W2022109007 @default.
• W4226156778 cites W2031351641 @default.
• W4226156778 cites W2035346924 @default.
• W4226156778 cites W2036778816 @default.
• W4226156778 cites W2042091518 @default.
• W4226156778 cites W2042374015 @default.
• W4226156778 cites W2050942978 @default.
• W4226156778 cites W2061669081 @default.
• W4226156778 cites W2064889388 @default.
• W4226156778 cites W2066860533 @default.
• W4226156778 cites W2078237173 @default.
• W4226156778 cites W2084300295 @default.
• W4226156778 cites W2089047115 @default.
• W4226156778 cites W2094993869 @default.
• W4226156778 cites W2101751531 @default.
• W4226156778 cites W2118249259 @default.
• W4226156778 cites W2119230710 @default.
• W4226156778 cites W2125679424 @default.
• W4226156778 cites W2131025532 @default.
• W4226156778 cites W2132458770 @default.
• W4226156778 cites W2136067436 @default.
• W4226156778 cites W2143532751 @default.
• W4226156778 cites W2143734513 @default.
• W4226156778 cites W2143999957 @default.
• W4226156778 cites W2146309723 @default.
• W4226156778 cites W2151182129 @default.
• W4226156778 cites W2153088784 @default.
• W4226156778 cites W2155119821 @default.
• W4226156778 cites W2156957181 @default.
• W4226156778 cites W2163238567 @default.
• W4226156778 cites W2163967299 @default.
• W4226156778 cites W2167928742 @default.
• W4226156778 cites W2247856738 @default.
• W4226156778 cites W2414068187 @default.
• W4226156778 cites W2473786944 @default.
• W4226156778 cites W2480680997 @default.
• W4226156778 cites W2565468745 @default.
• W4226156778 cites W2697100744 @default.
• W4226156778 cites W2762801440 @default.
• W4226156778 cites W2783493428 @default.
• W4226156778 cites W2788315630 @default.
• W4226156778 cites W2797670901 @default.
• W4226156778 cites W2801309543 @default.
• W4226156778 cites W2891991898 @default.
• W4226156778 cites W2898113690 @default.
• W4226156778 cites W2943634747 @default.
• W4226156778 cites W2963625961 @default.
• W4226156778 cites W2966047758 @default.
• W4226156778 cites W2978453381 @default.
• W4226156778 cites W2981484156 @default.
• W4226156778 cites W2989317082 @default.
• W4226156778 cites W3000655366 @default.
• W4226156778 cites W3002354512 @default.
• W4226156778 cites W3003262416 @default.
• W4226156778 cites W3008541467 @default.
• W4226156778 cites W3045490689 @default.
• W4226156778 cites W3165089710 @default.
• W4226156778 cites W3216326603 @default.
• W4226156778 cites W4251001509 @default.
• W4226156778 cites W4255014103 @default.
• W4226156778 doi "https://doi.org/10.3310/zdeg6110" @default.
• W4226156778 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35435818" @default.
• W4226156778 hasPublicationYear "2022" @default.
• W4226156778 type Work @default.
• W4226156778 citedByCount "5" @default.
• W4226156778 countsByYear W42261567782023 @default.
• W4226156778 crossrefType "journal-article" @default.
• W4226156778 hasAuthorship W4226156778A5003522548 @default.
• W4226156778 hasAuthorship W4226156778A5010249392 @default.

• next